AnaptysBio/$ANAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
$ANAB
Sector
Primary listing
Employees
136
Headquarters
Website
AnaptysBio Metrics
BasicAdvanced
$564M
-
-$4.46
-0.19
-
Price and volume
Market cap
$564M
Beta
-0.19
52-week high
$38.47
52-week low
$12.21
Average daily volume
475K
Financial strength
Current ratio
8.216
Quick ratio
8.082
Long term debt to equity
-770.027
Total debt to equity
-774.5
Interest coverage (TTM)
-1.22%
Profitability
EBITDA (TTM)
-85.559
Gross margin (TTM)
-33.00%
Net profit margin (TTM)
-107.66%
Operating margin (TTM)
-69.94%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$910,000
Management effectiveness
Return on assets (TTM)
-14.12%
Return on equity (TTM)
760.85%
Valuation
Price to revenue (TTM)
4.855
Price to book
-12.59
Price to tangible book (TTM)
-12.59
Price to free cash flow (TTM)
-4.668
Free cash flow yield (TTM)
-21.42%
Free cash flow per share (TTM)
-4.312
Growth
Revenue change (TTM)
304.17%
Earnings per share change (TTM)
-29.62%
3-year revenue growth (CAGR)
72.28%
10-year revenue growth (CAGR)
20.65%
3-year earnings per share growth (CAGR)
4.64%
10-year earnings per share growth (CAGR)
47.56%
What the Analysts think about AnaptysBio
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
AnaptysBio Financial Performance
Revenues and expenses
AnaptysBio Earnings Performance
Company profitability
AnaptysBio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $564M as of August 30, 2025.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of August 30, 2025.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of August 30, 2025.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of -0.19. This means that it has an inverse relation to market volatility.